HELICOBACTER

Scope & Guideline

Advancing Gastroenterology Through Innovative Research

Introduction

Explore the comprehensive scope of HELICOBACTER through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore HELICOBACTER in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN1083-4389
PublisherWILEY
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1996 to 2024
AbbreviationHELICOBACTER / Helicobacter
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address111 RIVER ST, HOBOKEN 07030-5774, NJ

Aims and Scopes

The journal 'HELICOBACTER' primarily focuses on research related to the bacterium *Helicobacter pylori*, its associated infections, treatment methodologies, and the implications of these infections on gastric health. It aims to disseminate high-quality research that contributes to the understanding and management of *H. pylori* infections.
  1. Clinical Management of *Helicobacter pylori*:
    Research on various treatment regimens, including empirical and tailored therapies, as well as the effectiveness of novel medications like vonoprazan and bismuth-containing therapies.
  2. Antibiotic Resistance Studies:
    Investigation into the resistance patterns of *H. pylori* to various antibiotics, including studies on the genetic and phenotypic resistance mechanisms.
  3. Gastric Cancer and Related Complications:
    Exploration of the relationship between *H. pylori* infection and gastric cancer, including studies on screening, prevention, and the impact of eradication therapies on cancer risk.
  4. Microbiota Interaction and Metabolism:
    Research on how *H. pylori* interacts with the gastric microbiota and its effects on metabolic processes and gastrointestinal health.
  5. Immunological Responses and Vaccine Development:
    Focus on the immune response elicited by *H. pylori* and the development of potential vaccines and immunotherapies.
  6. Epidemiological Studies:
    Surveys and studies analyzing the prevalence of *H. pylori* infection across different populations, age groups, and geographical regions.
The journal has seen a shift towards certain trending and emerging themes that reflect the latest advancements and interests in the field of *H. pylori* research.
  1. Novel Therapeutics and Treatment Strategies:
    A growing focus on innovative treatment strategies, including the use of dual therapy with new drugs like vonoprazan and the evaluation of non-antibiotic options.
  2. Personalized Medicine Approaches:
    Emerging research on tailoring treatment plans based on individual patient factors, such as genetic makeup and antibiotic susceptibility, indicating a shift towards personalized medicine.
  3. Impact of Microbiota on Treatment Outcomes:
    Increased attention on how the gut microbiome influences treatment efficacy and patient outcomes, reflecting a growing understanding of microbial interactions.
  4. Global Antibiotic Resistance Trends:
    An expanding body of work dedicated to tracking antibiotic resistance patterns globally, particularly in pediatric and elderly populations, highlights the public health implications of *H. pylori* infections.
  5. Integration of Artificial Intelligence in Treatment:
    The introduction of AI technologies in predicting treatment outcomes and enhancing patient education materials indicates a trend towards leveraging technology in clinical settings.
  6. Long-Term Effects of Eradication Therapy:
    Research examining the long-term outcomes and potential complications following *H. pylori* eradication therapy, including its impact on gastric health and cancer risk.

Declining or Waning

While the journal continues to publish a wide range of topics, certain areas of research seem to be declining in frequency or prominence in recent publications.
  1. Basic Microbiological Studies:
    There has been a noticeable decrease in fundamental research focusing solely on the microbiological characteristics of *H. pylori*, such as its metabolism and basic physiology, as the focus shifts to clinical and therapeutic applications.
  2. Single-Agent Therapy Studies:
    Research centered on single-agent therapies for *H. pylori* eradication is becoming less common, as combination therapies and novel regimens are now preferred.
  3. Older Eradication Regimens:
    There is a waning interest in older treatment regimens and their comparative effectiveness, with current research emphasizing newer therapies and their long-term outcomes.
  4. Animal Model Studies:
    The use of animal models for *H. pylori* research appears to be decreasing, potentially as clinical studies gain more relevance and priority.
  5. Non-Gastrointestinal Implications:
    Studies exploring the implications of *H. pylori* infection beyond the gastrointestinal tract, such as its potential links to systemic diseases, are being published less frequently.

Similar Journals

Antibiotics-Basel

Advancing antibiotic research for a healthier tomorrow.
Publisher: MDPIISSN: 2079-6382Frequency: 12 issues/year

Antibiotics-Basel is a prestigious multidisciplinary journal published by MDPI, dedicated to advancing the field of antibiotic research and management. Since its inception in 2012 as an Open Access publication, the journal has established itself as a vital resource for researchers and professionals, offering an accessible platform for the dissemination of innovative findings in Biochemistry, Infectious Diseases, Microbiology, and Pharmacology. With a solid impact in its category, Antibiotics-Basel holds a Q1 ranking in critical areas such as Pharmacology and Pharmacology, Toxicology and Pharmaceutics, making it an influential journal in its field. The journal publishes high-quality research articles, reviews, and communications that are essential for advancing our understanding of antibiotic mechanisms, resistance, and therapeutic applications. Researchers are invited to submit their manuscript to contribute to this growing body of knowledge and collaborate in the fight against antibiotic resistance and infectious diseases.

BIOORGANIC CHEMISTRY

Catalyzing advancements in drug discovery and biochemistry.
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCEISSN: 0045-2068Frequency: 12 issues/year

BIOORGANIC CHEMISTRY, published by Academic Press Inc., a prestigious imprint of Elsevier Science, represents a cornerstone in the fields of biochemistry, organic chemistry, and drug discovery. With an impressive Scopus rank placing it in the top quartiles across critical categories—including Q2 for Biochemistry and Drug Discovery, and Q1 for Organic Chemistry—this journal has established itself as a vital resource for researchers, professionals, and students alike. Featuring a diverse array of articles that explore innovative methodologies and emerging trends from 1971 to the present, BIOORGANIC CHEMISTRY effectively bridges the gap between laboratory research and practical applications. Although not an Open Access journal, its rigorous peer-review process ensures the delivery of high-quality, impactful research that drives advances in the understanding and application of biochemistry. With an aim to facilitate scientific discourse and collaboration, it invites contributions that further the exploration of chemical processes within biological systems.

World Journal of Gastrointestinal Oncology

Connecting research and practice in gastrointestinal health and cancer.
Publisher: BAISHIDENG PUBLISHING GROUP INCISSN: 1948-5204Frequency: 12 issues/year

World Journal of Gastrointestinal Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a pivotal resource in the evolving fields of gastroenterology and oncology, particularly focused on the intricate relationship between gastrointestinal disorders and cancer. Established in 2014, the journal continues to publish influential research, boasting a commendable Q2 ranking in both the gastroenterology and oncology categories for 2023, which underscores its importance in these critical medical domains. With a diverse range of topics and studies, it serves as an essential platform for researchers, healthcare professionals, and students aiming to stay informed about the latest advancements and innovations in gastrointestinal oncology. Though currently not classified as open access, the journal's rigorous peer-review process ensures the dissemination of high-quality research that significantly contributes to clinical practice and patient care. Its positioning in the Scopus rankings also highlights its competitive standing within the scientific community, fostering discussions that are crucial for advancing both fields. Explore the latest insights and findings to enhance your understanding and contribute to the ongoing dialogue in gastrointestinal health and oncology.

Journal of Clinical Tuberculosis and Other Mycobacterial Diseases

Advancing Knowledge in Mycobacterial Diseases
Publisher: ELSEVIERISSN: 2405-5794Frequency: 4 issues/year

Journal of Clinical Tuberculosis and Other Mycobacterial Diseases is a leading peer-reviewed journal dedicated to advancing the field of infectious diseases, particularly focusing on tuberculosis and other mycobacterial infections. Published by ELSEVIER in the United Kingdom with an impressive open access model since 2015, this journal aims to provide a platform for the dissemination of high-quality research, clinical findings, and innovative methodologies in the management of mycobacterial diseases. With a commendable impact, the journal currently holds a Q2 ranking in multiple categories including Infectious Diseases and Pulmonary and Respiratory Medicine, reflecting its influence in the academic community. The journal is dedicated to serving researchers, healthcare professionals, and students by offering access to essential information that can improve patient outcomes and enhance public health strategies. As the field of mycobacterial diseases continues to evolve, Journal of Clinical Tuberculosis and Other Mycobacterial Diseases remains a crucial resource for those seeking to remain at the forefront of research and clinical practice.

Trends in Cancer

Transforming Cancer Research Through Scholarly Excellence
Publisher: CELL PRESSISSN: 2405-8025Frequency: 12 issues/year

Trends in Cancer is a leading journal published by CELL PRESS, dedicated to advancing the field of cancer research and oncology. Since its inception in 2015, the journal has rapidly gained a reputation for excellence, securing both Q1 rankings in Cancer Research and Oncology categories for 2023 and boasting impressive Scopus ranks—#13 out of 404 in Medicine Oncology and #9 out of 230 in Biochemistry, Genetics and Molecular Biology, thus placing it in the top 4% of its field. The journal aims to publish high-quality, innovative research that offers new insights into cancer biology and treatment strategies. With a commitment to scholarly rigor and a broad scope that encompasses molecular mechanisms to therapeutic approaches, Trends in Cancer serves as an essential resource for researchers, professionals, and students eager to stay informed about the latest developments in cancer science. Although it is not an open-access journal, its contributions are pivotal in shaping the future of cancer research.

DIGESTIVE DISEASES

Exploring the Frontiers of Digestive Medicine.
Publisher: KARGERISSN: 0257-2753Frequency: 6 issues/year

DIGESTIVE DISEASES, published by KARGER, stands as a leading international journal dedicated to the field of gastroenterology and digestive health. With an ISSN of 0257-2753 and E-ISSN 1421-9875, the journal has been providing a platform for high-quality research since its inception in 1983, continuing to disseminate groundbreaking findings and insights through to 2024. Positioned in the second quartile (Q2) of both the gastroenterology and miscellaneous medicine categories as of 2023, DIGESTIVE DISEASES is recognized for its rigorous peer-review process and its contributions to advancing clinical and experimental gastroenterological knowledge. Its Scopus ranking at #62 out of 167 in the gastroenterology field reflects its significant impact, as it reaches a notable 63rd percentile among its peers. While it does not currently offer open access options, its subscription model ensures that vital research is available to professionals and institutions committed to the field. The journal serves as an essential resource for researchers, clinicians, and students alike who seek to deepen their understanding of digestive disorders and their implications in medicine.

Microbial Drug Resistance

Illuminating the Path to Effective Antimicrobial Strategies
Publisher: MARY ANN LIEBERT, INCISSN: 1076-6294Frequency: 10 issues/year

Microbial Drug Resistance, published by MARY ANN LIEBERT, INC, is a pivotal journal that explores the critical intersection of microbiology and pharmacology with a keen focus on antibiotic resistance and related issues. Since its inception in 1995, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for innovative studies that inform the global response to antimicrobial resistance. With a commendable position in the Category Quartiles, ranked Q2 in Medicine (miscellaneous) and Q2 in Pharmacology for 2023, it caters to a multidisciplinary audience by addressing the implications of microbial resistance within various medical contexts. Although currently non-Open Access, the journal allows subscribers and institutions to access high-quality, peer-reviewed research, directly impacting policy and practice in healthcare settings. Committed to advancing our understanding and combating the challenges posed by resistant microbes, Microbial Drug Resistance remains an essential publication in the fields of microbiology, immunology, and pharmacology.

Journal of the Pediatric Infectious Diseases Society

Empowering professionals with vital research and insights.
Publisher: OXFORD UNIV PRESSISSN: 2048-7193Frequency: 4 issues/year

Journal of the Pediatric Infectious Diseases Society, published by Oxford University Press, stands as a pivotal platform for advancing knowledge in the realm of pediatric infectious diseases. With an ISSN of 2048-7193 and an E-ISSN of 2048-7207, this esteemed journal has garnered significant recognition in the academic community, achieving influential rankings such as Q1 in Pediatrics, Perinatology and Child Health and Q2 in Infectious Diseases. With converged years from 2012 to 2024, it aims to publish cutting-edge research, reviews, and clinical practices that address the challenges and innovations in the field. The journal's strong performance, reflected in its Scopus ranks (33rd percentile in Pediatrics and 97th in Infectious Diseases), underscores its impact on the global healthcare landscape. As a non-open access journal, it provides exclusive content essential for researchers, medical professionals, and students dedicated to enhancing pediatric healthcare outcomes.

ANTIVIRAL THERAPY

Advancing the frontier of antiviral research.
Publisher: SAGE PUBLICATIONS LTDISSN: 1359-6535Frequency: 8 issues/year

ANTIVIRAL THERAPY is a prominent academic journal dedicated to the field of infectious diseases and pharmacology, published by SAGE Publications Ltd in the United Kingdom. Since its inception in 1996, this journal has become an essential platform for disseminating cutting-edge research and innovative therapeutic approaches for viral infections, making significant contributions to advancements in medical science. With an HIndex indicating the quality and influence of its published work, ANTIVIRAL THERAPY holds prestigious rankings in its categories, including Q3 in Infectious Diseases and Pharmacology as of 2023. While it currently does not offer open access, the journal provides valuable insights that are crucial for researchers, healthcare professionals, and students engaged in antiviral research and treatment strategies. As it converges towards 2024, the journal continues to play a vital role in shaping the understanding and management of viral diseases, making it a critical resource for anyone involved in this important field of study.

JOURNAL OF CHEMOTHERAPY

Advancing the Frontiers of Chemotherapy Research
Publisher: TAYLOR & FRANCIS LTDISSN: 1120-009XFrequency: 6 issues/year

Journal of Chemotherapy is a distinguished peer-reviewed academic journal published by Taylor & Francis Ltd, focusing on the dynamic fields of infectious diseases, oncology, and pharmacology. With its ISSN 1120-009X and E-ISSN 1973-9478, this journal has been at the forefront of chemotherapy research since its inception in 1989 and continues to play a vital role in advancing medical science through rigorous studies and reviews. It currently holds a respectable position in various Scopus categories, ranked Q3 in several important disciplines, reflecting its commitment to providing quality research. Although it operates under a subscription model, Journal of Chemotherapy remains a crucial resource for practitioners and academics alike, facilitating knowledge exchange and innovation in the treatment of diseases through chemotherapy. With access to the latest findings and therapeutic advancements, this journal is a must-read for researchers, medical professionals, and students seeking to enhance their understanding of emerging trends in chemotherapy.